Final height after gonadotrophin releasing hormone agonist treatment for central precocious puberty: The Dutch experience

Final height (FH) data of 96 children (87 girls) treated with GnRH agonist for central precocious puberty were studied. In girls mean FH exceeded init ial height prediction by 7.4 (5.7) cm (p < 0.001); FH was significantly low er than target height, but still in the genetic target range. When treatmen t started < 6 years of age, height gain was significantly higher than when started > 8 years of age. Bone age (BA) and chronological age (CA) at start of treatment, as well as BA advance at cessation of treatment, were the mo st important variables influencing height gain in multiple regression analy sis. BA advance at start of treatment was most important in simple correlat ion. In girls, GnRHa treatment seems to restore FH into the target range. A younger age and advanced bone age at start of treatment are associated wit h more height gain from GnRHa treatment.